Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2025: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2024: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2023: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Outline of Annual Research Achievements |
申請者の関与した研究は、主に唾液腺悪性腫瘍に関する研究で、成果論文では病理検体を分子病理学的に解析し、腫瘍悪性度や予後との関係性について考察している。 ①Shimoda H, Teshima M, Murase T, et al. Prognostic scores for patients with salivary adenoid cystic carcinoma without lymph node metastasis. Oral Oncol. 2023;145:106491. ②Ueda K, Murase T, Kawakita D, et al. The Landscape of MYB/MYBL1- and Peri-MYB/MYBL1-Associated Rearrangements in Adenoid Cystic Carcinoma. Mod Pathol. 2023;36:100274. ③Murase T, Nakano S, Sakane T, et al. Thymic Mucoepidermoid Carcinoma: A Clinicopathologic and Molecular Study. Am J Surg Pathol. 2022;46:1160-1169. ④Murase T, Ishibashi K, Okumura Y, et al. Pleomorphic adenoma: detection of PLAG1 rearrangement-positive tumor components using whole-slide fluorescence in situ hybridization. Hum Pathol. 2022;120:26-34. ⑤Nakano S, Okumura Y, Murase T, et al. Salivary mucoepidermoid carcinoma: histological variants, grading systems, CRTC1/3-MAML2 fusions, and clinicopathological features. Histopathology. 2022;80:729-735. ⑥Morita N, Murase T, Ueda K, et al. Pathological evaluation of tumor grade for salivary adenoid cystic carcinoma: A proposal of an objective grading system. Cancer Sci. 2021;112:1184-1195. ⑦Iwaki S, Kawakita D, Murase T, et al. Comprehensive genomic profiling of salivary gland carcinoma: Analysis of the Center for Cancer Genomics and Advanced Therapeutics database in Japan. Int J Cancer. 2024 Apr 30. doi:10.1002/ijc.34972. Epub. PMID: 38686510.
|